BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37586769)

  • 1. ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis.
    Mann JE; Lucca L; Austin MR; Merkin RD; Robert ME; Al Bawardy B; Raddassi K; Aizenbud L; Joshi NS; Hafler DA; Abraham C; Herold KC; Kluger HM
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-Gamma-Producing CD8
    Sasson SC; Slevin SM; Cheung VTF; Nassiri I; Olsson-Brown A; Fryer E; Ferreira RC; Trzupek D; Gupta T; Al-Hillawi L; Issaias ML; Easton A; Campo L; FitzPatrick MEB; Adams J; Chitnis M; Protheroe A; Tuthill M; Coupe N; Simmons A; Payne M; Middleton MR; Travis SPL; ; Fairfax BP; Klenerman P; Brain O
    Gastroenterology; 2021 Oct; 161(4):1229-1244.e9. PubMed ID: 34147519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis.
    Westdorp H; Sweep MWD; Gorris MAJ; Hoentjen F; Boers-Sonderen MJ; van der Post RS; van den Heuvel MM; Piet B; Boleij A; Bloemendal HJ; de Vries IJM
    Front Immunol; 2021; 12():768957. PubMed ID: 34777387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis.
    Thomas MF; Slowikowski K; Manakongtreecheep K; Sen P; Samanta N; Tantivit J; Nasrallah M; Zubiri L; Smith NP; Tirard A; Ramesh S; Arnold BY; Nieman LT; Chen JH; Eisenhaure T; Pelka K; Song Y; Xu KH; Jorgji V; Pinto CJ; Sharova T; Glasser R; Chan P; Sullivan RJ; Khalili H; Juric D; Boland GM; Dougan M; Hacohen N; Li B; Reynolds KL; Villani AC
    Nat Med; 2024 May; 30(5):1349-1362. PubMed ID: 38724705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis.
    Hone Lopez S; Kats-Ugurlu G; Renken RJ; Buikema HJ; de Groot MR; Visschedijk MC; Dijkstra G; Jalving M; de Haan JJ
    Virchows Arch; 2021 Dec; 479(6):1119-1129. PubMed ID: 34338882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
    Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
    Kim H; Park S; Han KY; Lee N; Kim H; Jung HA; Sun JM; Ahn JS; Ahn MJ; Lee SH; Park WY
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions.
    Dougan M
    Immunol Rev; 2023 Sep; 318(1):11-21. PubMed ID: 37455375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.
    Luoma AM; Suo S; Williams HL; Sharova T; Sullivan K; Manos M; Bowling P; Hodi FS; Rahma O; Sullivan RJ; Boland GM; Nowak JA; Dougan SK; Dougan M; Yuan GC; Wucherpfennig KW
    Cell; 2020 Aug; 182(3):655-671.e22. PubMed ID: 32603654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
    Zhu H; Galdos FX; Lee D; Waliany S; Huang YV; Ryan J; Dang K; Neal JW; Wakelee HA; Reddy SA; Srinivas S; Lin LL; Witteles RM; Maecker HT; Davis MM; Nguyen PK; Wu SM
    Circulation; 2022 Jul; 146(4):316-335. PubMed ID: 35762356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations.
    Kotwal A; Gustafson MP; Bornschlegl S; Kottschade L; Delivanis DA; Dietz AB; Gandhi M; Ryder M
    Thyroid; 2020 Oct; 30(10):1440-1450. PubMed ID: 32323619
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
    Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
    J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Miao K; Zhang X; Wang H; Si X; Ni J; Zhong W; Zhao J; Xu Y; Chen M; Pan R; Wang M; Zhang L
    Front Immunol; 2022; 13():912180. PubMed ID: 35844502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis.
    Gupta T; Antanaviciute A; Hyun-Jung Lee C; Ottakandathil Babu R; Aulicino A; Christoforidou Z; Siejka-Zielinska P; O'Brien-Ball C; Chen H; Fawkner-Corbett D; Geros AS; Bridges E; McGregor C; Cianci N; Fryer E; Alham NK; Jagielowicz M; Santos AM; Fellermeyer M; Davis SJ; Parikh K; Cheung V; Al-Hillawi L; Sasson S; Slevin S; Brain O; ; Fernandes RA; Koohy H; Simmons A
    Cancer Cell; 2024 May; 42(5):797-814.e15. PubMed ID: 38744246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P067 Immune Checkpoint Inhibitor Colitis in a Community-Based Hospital System.
    Rampersad A; Abrams G; Bauer C
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17-S18. PubMed ID: 37461984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of CD4
    He JY; Kim YJ; Mennillo E; Rusu I; Bain J; Rao AA; Andersen C; Law K; Yang H; Tsui J; Shen A; Davidson B; Kushnoor D; Shi Y; Fan F; Cheung A; Zhang L; Fong L; Combes AJ; Pisco AO; Kattah MG; Oh DY
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
    Gehrcken L; Sauerer T; Schaft N; Dörrie J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.